Current status and future challenges of HPV preventive vaccine of cervical cancer

doi:10.3760/cma.j.issn.1673-422X.2019.05.012

Abstract

Abstract: Human papillomavirus (HPV) vaccine is approved by the the U. S. Food and Drug Administration in 2006 for female cancer prevention. There are currently three types of prophylactic HPV vaccines, and its application in developed countries can significantly reduce HPV infection rates and cervical lesion rates. In developing countries, HPV vaccination rates are low due to lack of knowledge of cervical cancer and funds. At the same time, concerns about vaccine safety have led to a reduction in vaccination rates in developed countries. Countries are facing the challenge of increasing vaccination rates.

Key words: Papillomaviridae, Uterine cervical neoplasms, Papillomavirus vaccines, Primary prevention

Li Ang, Wei Fang. Current status and future challenges of HPV preventive vaccine of cervical cancer[J]. Journal of International Oncology, 2019, 46(5): 307-310.

References

［1］ Burk RD, Harari A, Chen Z. Human papillomavirus genome variants［J］. Virology, 2013, 445(1-2): 232-243. DOI: 10.1016/j.virol.2013.07.018. ［2］ Shen Y, Gong JM, Li YQ, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China［J］. Clin Chim Acta, 2013, 415: 297-301. DOI: 10.1016/j.cca.2012.11.005. ［3］ Dela Cruz MRI, Tsark JAU, Chen JJ, et al. Human papillomavirus (HPV) vaccination motivators, barriers, and brochure preferences among parents in multicultural Hawai′i: a qualitative study［J］. J Cancer Educ, 2017, 32(3): 613-621. DOI: 10.1007/s13187-016-1009-2. ［4］ Kester LM, Zimet GD, Fortenberry JD, et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for nonvaccination［J］. Matern Child Health J, 2013, 17(5): 879-885. DOI: 10.1007/s10995-012-1066-z. ［5］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［6］ Garland SM, Kjaer SK, Muoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of realworld experience［J］. Clin Infect Dis, 2016, 63(4): 519-527. DOI: 10.1093/cid/ciw354. ［7］ Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States［J］. Pediatrics, 2016, 137(3): e20151968. DOI: 10.1542/peds.2015-1968. ［8］ Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines［J］. J Natl Cancer Inst, 2015, 107(6): djv086. DOI: 10.1093/jnci/djv086. ［9］ Fernandes R, Potter BK, Little J. Attitudes of undergraduate university women towards HPV vaccination: a cross-sectional study in Ottawa, Canada［J］. BMC Womens Health, 2018, 18(1): 134. DOI: 10.1186/s12905-018-0622-0. ［10］ Gilbert NL, Gilmour H, Dubé E, et al. Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: results from the Childhood national immunization coverage survey, 2013［J］. Hum Vaccin Immunother, 2016, 12(6): 1484-1490. DOI: 10.1080/21645515.2016.1153207. ［11］ Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus types among 18to 35year old Australian women 9 years following implementation of vaccination［J］. J Infect Dis, 2018, 217(10): 1590-1600. DOI: 10.1093/infdis/jiy075. ［12］ Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study［J］. Lancet Public Health, 2019, 4(1): e19-e27. DOI: 10.1016/S24682667(18)30183X. ［13］ Qendri V, SchurinkVan′t Klooster TM, Bogaards JA, et al. Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPVrelated disease prevention［J］. Expert Rev Vaccines, 2018, 17(12): 1093-1104. DOI: 10.1080/14760584.2018.1547196. ［14］ Mennini FS, Bonanni P, Bianic F, et al. Costeffectiveness analysis of the ninevalent HPV vaccine in Italy［J］. Cost Eff Resour Alloc, 2017, 15: 11. DOI: 10.1186/s12962-017-0073-8. ［15］ Largeron N, Petry KU, Jacob J, et al. An estimate of the public health impact and costeffectiveness of universal vaccination with a 9valent HPV vaccine in Germany［J］. Expert Rev Pharmacoecon Outcomes Res, 2017, 17(1): 85-98. DOI: 10.1080/14737167.2016.1208087. ［16］ Mesher D, Panwar K, Thomas SL, et al. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing crosssectional study［J］. BMJ open, 2016, 6(2): e009915. DOI: 10.1136/bmjopen-2015-009915. ［17］ BaldurFelskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasianationwide follow-up of young Danish women［J］. J Natl Cancer Inst, 2014, 106(3): djt460. DOI: 10.1093/jnci/djt460. ［18］ Feiring B, Laake I, Christiansen IK, et al. Substantial decline in prevalence of vaccinetype and nonvaccinetype human papilloma-virus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway［J］. J Infect Dis, 2018, 218(12): 19001910. DOI: 10.1093/infdis/jiy432. ［19］ Konno R, Konishi H, Sauvaget C, et al. Effectiveness of HPV vaccination against high grade cervical lesions in Japan［J］. Vaccine, 2018, 36(52): 7913-7915. DOI: 10.1016/j.vaccine.2018.05.048. ［20］ Kim MA, Han GH, Kim JH, et al. Current status of human papillomavirus infection and introduction of vaccination to the national immunization program in Korea: an overview［J］. J Korean Med Sci, 2018, 33(52): e331. DOI: 10.3346/jkms.2018.33.e331. ［21］ Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV16/18 AS04adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial［J］. Int J Cancer, 2014, 135(11): 2612-2622. DOI: 10.1002/ijc.28897. ［22］ Wei L, Xie X, Liu J, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebocontrolled trial with 78-month follow-up［J］. Vaccine, 2018, pii: S0264-410X(18)31116-2. DOI: 10.1016/j.vaccine.2018.08.009. ［23］ Buang SN, Ja'afar S, Pathmanathan I, et al. Human papillomavirus immunisation of adolescent girls: improving coverage through multisectoral collaboration in Malaysia［J］. BMJ, 2018, 363: k4602. DOI: 10.1136/bmj.k4602. ［24］ Garon J, Wuddhika IV, Sreenivasan N, et al. Communitybased household assessment of human papillomavirus (HPV) vaccination coverage and acceptabilityHPV vaccine demonstration program, Cambodia2017［J］. Vaccine, 2019, 37(9): 1202-1208. DOI: 10.1016/j.vaccine.2018.12.052. ［25］ Bruni L, Diaz M, BarrionuevoRosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis［J］. Lancet Glob Health, 2016, 4(7): e453e463. DOI: 10.1016/S2214-109X(16)30099-7. ［26］ Owsianka B, Gańczak M. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide［J］. Przegl Epidemiol, 2015, 69(1): 53-58, 151-155. ［27］ Kalinowski P, Grzdziel A. HPV vaccinations in Lublin region, Poland［J］. Postepy Hig Med Dosw (Online), 2017, 71(0): 92-97. ［28］ Latsuzbaia A, Arbyn M, Weyers S, et al. Human papillomavirus vaccination coverage in Luxembourgimplications of lowering and restricting target age groups［J］. Vaccine, 2018, 36(18): 2411-2416. DOI: 10.1016/j.vaccine.2018.03.054. ［29］ Klinsupa W, Pensuk P, Thongluan J, et al. O16.3 Hpv vaccine introduction in Thailand［J］. Sex Transm Infect, 2015, 91 Suppl 2: A61. DOI: org/10.1136/sextrans-2015-052270.167. ［30］ Perez S, Zimet GD, Tatar O, et al. Human papillomavirus vaccines: successes and future challenges［J］. Drugs, 2018, 78(14): 1385-1396. DOI: 10.1007/s40265-018-0975-6. ［31］ Hanley SJ, Yoshioka E, Ito Y, et al. HPV vaccination crisis in Japan［J］. Lancet, 2015, 385(9987): 2571. DOI: 10.1016/S0140-6736(15)61152-7. ［32］ Juntasopeepun P, Thana K. Parental acceptance of HPV vaccines in Chiang Mai, Thailand［J］. Int J Gynaecol Obstet, 2018, 142(3): 343-348. DOI: 10.1002/ijgo.12539.

[1]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[2]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[3]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[4]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[5]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[6]	Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 568-571.
[7]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[8]	Yuan Chenyang, Zhou Juying. Research progress on prognostic factors of cervical cancer [J]. Journal of International Oncology, 2022, 49(5): 307-313.
[9]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.
[10]	Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min. Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells [J]. Journal of International Oncology, 2021, 48(4): 206-211.
[11]	Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong. Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model [J]. Journal of International Oncology, 2021, 48(1): 35-40.
[12]	Ding Xuchao, Cao Lili. Common active targeting nano drug delivery systems for cervical cancer [J]. Journal of International Oncology, 2021, 48(1): 61-64.
[13]	Shu Hang, Xu Zhonghua, Zhu Haochen, Yang Yahui, Lyu Yin. Research progress of radiosensitivity in cervical cancer [J]. Journal of International Oncology, 2020, 47(8): 496-500.
[14]	Zheng Xin, Chen Xiaopin. Relationship between HPV and oropharyngeal cancer in China [J]. Journal of International Oncology, 2020, 47(3): 164-168.
[15]	Song Mingze, Cheng Yiming, Li Gang, Wang Zhenming, Li Shirong. Value of P16/Ki-67 double staining detection in screening cervical cancer and precancerous lesions [J]. Journal of International Oncology, 2020, 47(11): 675-681.